# A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto)

> **NCT02125344** · PHASE3 · COMPLETED · sponsor: **GBG Forschungs GmbH** · enrollment: 961 (actual)

## Conditions studied

- Tubular Breast Cancer Stage II
- Tubular Breast Cancer Stage III
- Mucinous Breast Cancer Stage II
- Breast Cancer Female NOS
- Invasive Ductal Breast Cancer
- HER2 Positive Breast Cancer
- Inflammatory Breast Cancer

## Interventions

- **DRUG:** non-pegylated liposomal doxorubicin
- **DRUG:** Carboplatin
- **DRUG:** Paclitaxel
- **DRUG:** Epirubicin
- **DRUG:** Cyclophosphamide
- **DRUG:** Pertuzumab
- **DRUG:** Trastuzumab
- **DRUG:** Ferric carboxymaltose

## Key facts

- **NCT ID:** NCT02125344
- **Lead sponsor:** GBG Forschungs GmbH
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12
- **Primary completion:** 2016-11
- **Final completion:** 2017-01-30
- **Target enrollment:** 961 (ACTUAL)
- **Last updated:** 2017-07-13

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02125344

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02125344, "A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02125344. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*